Trend of huge transactions of mergers and acquisitions in the pharmaceutical sector initiated last year continued into this year.
The US company AbbVie said it would buy the company Pharmacyclics for $ 21 billion. This will get access to the portfolio AbbVie oncology products because Pharmacyclics produces one of the best-selling drugs of this type, Imbruvicu, which is used in the treatment of leukemia. In this way AbbVie will reduce dependence on its range of drugs that are most reliant on Humira, a drug against rheumatoid arthritis, which has the largest share in AbbVieovoj sale.
